Upon joining the study, you will be randomly assigned to one of the treatment groups. This means you will either receive the new medication JNJ-77242113, a placebo, or the active comparator deucravacitinib. The assignment is random to ensure fairness and accuracy in the study results.

If you are assigned to the JNJ-77242113 group, you will take the medication orally in the form of a film-coated tablet. The exact dosage and frequency will be provided by the study team.

If you are in the deucravacitinib group, you will also take the medication orally as a film-coated tablet. The study team will inform you of the specific dosage and frequency.

If you are in the placebo group, you will take a tablet that looks like the medication but does not contain the active substance. This is to help compare the effects of the actual medication.

Throughout the study, you will have regular check-ups to monitor your health and the effects of the medication. These check-ups are important to ensure your safety and to gather data on the medication’s effectiveness.

At week 16, your condition will be evaluated to see if there has been an improvement. The primary goal is to achieve an IGA score of 0 or 1, which indicates clear or almost clear skin, and a significant improvement from the start of the study.

Another important measure is the PASI 90, which means a 90% improvement in your psoriasis condition compared to the beginning of the study.

Once the study period is over, you will have a final evaluation. This will help determine the overall effectiveness and safety of the medication you received.